MAPK1 and neurodegenerative disease: Additionally, in silico studies in investigating the potential utility of MAPK1 inhibition for Alzheimer’s treatment through computational modeling and virtual screening, identified potential peptide epitopes capable of disrupting pathological MAPK signaling that contributes neurodegenerative disease mechanisms [79].